The Dry Age-related Macular Degeneration market growth is driven by factors like increase in the prevalence of Dry Age-related Macular Degeneration, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Dry Age-related Macular Degeneration market report also offers comprehensive insights into the Dry Age-related Macular Degeneration market size, share, Dry Age-related Macular Degeneration epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dry Age-related Macular Degeneration market size growth forward.
Some of the key highlights from the Dry Age-related Macular Degeneration Market Insights Report:
Strategise your business goals by understanding market dynamics @ Dry Age-related Macular Degeneration Market Landscape
Dry Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged.
AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. One of the top four causes of blindness in the elderly is AMD. It is also the leading cause of irreversible blindness in the developed countries. A total population of about 170 million individuals is affected with AMD globally, thus being the third leading cause of vision loss in the world.
Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. No symptoms appear during the early stage of the disease. During this initial stage, an ophthalmologist can detect drusen long before symptoms occur. Symptoms that typically occur during the intermediate stage include minor alterations in eyesight; however, many people do not have any symptoms at this time. Some people see black or grey areas in the middle of their visual field or have difficulty adapting from a brightly illuminated environment to a dark environment.
AMD is a complex multifactorial disease whose pathogenesis is incompletely understood and evolving, with a detailed evaluation behind the scope of this review. Several factors are believed to contribute to its pathogenesis, including genetic, oxidative stress, environmental, inflammatory and ischaemic. The presence of drusen is considered the hallmark of earlier stages of AMD, which may enlarge, become confluent and evolve to drusenoid retinal pigmented epithelium (RPE) detachments.
This causes a disruption in the interaction between Bruch’s membrane and RPE, inhibiting RPE function, including the crucial ability to transport photoreceptor debris across Bruch’s membrane to the choriocapillaris, further facilitaing accumulation of lipofuscin and other related products including A2E. Drusen contains several proinflammatory factors including complement pathway components (and lipofuscin-related products), which have been identified as one of the main contributors to AMD development.
Currently, clinicians monitor morphological changes in the retina/RPE/choroid by fundus exam, color fundus photography, FAF, OCT, and infrared (IR) reflectance. In the past two decades, OCT140 imaging technologies have had a profound impact on early detection, monitoring of progression, and treatment-efficacy evaluation of dry AMD. The current generation of commercialized OCT systems, SD-OCT, provides volumetric and cross-sectional views of the retina facilitating the visualization, measurement, monitoring, and phenotyping of the retinal layers and RPE,141–143 hyperreflective foci,144 GA,145,146 and drusen147 in eyes with dry AMD.
Do you know the treatment paradigms for different countries? Download our Dry Age-related Macular Degeneration Market Sample Report
Dry Age-related Macular Degeneration Epidemiology Segmentation
DelveInsight’s Dry Age-related Macular Degeneration market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dry Age-related Macular Degeneration historical patient pools and forecasted Dry Age-related Macular Degeneration patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dry Age-related Macular Degeneration Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Dry Age-related Macular Degeneration Epidemiological Insights
Dry Age-related Macular Degeneration Treatment Market
The Dry Age-related Macular Degeneration market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dry Age-related Macular Degeneration market trends by analyzing the impact of current Dry Age-related Macular Degeneration therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Dry Age-related Macular Degeneration market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dry Age-related Macular Degeneration market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Dry Age-related Macular Degeneration market in 7MM is expected to witness a major change in the study period 2019-2032.
Dry Age-related Macular Degeneration Emerging Drugs
ALK-001: Alkeus Pharmaceuticals
ALK-001 is once-a-day oral drug candidate currently being tested for the treatment of geographic atrophy (advanced form of dry AMD) and Stargardt disease. Toxic vitamin A aggregates called “dimers” are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers.
Elamipretide: Stealth BioTherapeutics
Elamipretide (Stealth BioTherapeutics) is a novel tetrapeptide drug currently in development for both common and orphan diseases that involve dysfunction of the mitochondria, the cellular organelles that generates chemical energy in the form of adenosine triphosphate (ATP). At the cellular level, mitochondrial dysfunction causes loss of ATP production, increased levels of reactive oxygen species (eg, superoxide), calcium dysregulation, and, if prolonged, cell death.Elamipretide, given as systemic injection, penetrates tissues and cells and enters the mitochondria, where it reverses mitochondrial dysfunction (improved ATP production, restored mitochondrial membrane potential, normal calcium flux, and reduced superoxide generation).
CPCB-RPE1: Regenerative Patch Technologies
Regenerative Patch Technologies has developed composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch’s membrane.
AAV.sFH: Aevitas Therapeutics
AAV.sFH, is an investigational drug being developed by Aevitas Therapeutics. Aevitas advances AAV gene therapies of short-form human factor H (sFH) to restore homeostasis in disorders of complement dysregulation: dry age-related macular degeneration (Dry AMD), atypical hemolytic uremic syndrome (aHUS) and other disorders. sFH restored complement regulation in eyes of FH knockout mice with subretinal administration.
Supraphysiological expression of sFH with subretinal administration was shown in non-human primate eye. Good vector genome transfer to ocular target tissues with intravitreal administration was demonstrated in Yorkshire pigs. Transgene product sFH was present in all eye compartments with potentially clinically relevant FH levels in the porcine eye. Currently, the drug is in Preclinical stage of development for the treatment of Dry AMD.
Dry Age-related Macular Degeneration Key Companies
For more information, visit Dry Age-related Macular Degeneration Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Dry Age-related Macular Degeneration Market Report:
Key Questions Answered in the Dry Age-related Macular Degeneration Market Report 2032:
Table of Contents:
1 Dry Age-related Macular Degeneration Market Key Comprehensive Insights
2 Dry Age-related Macular Degeneration Market Report Introduction
3 Competitive Intelligence Analysis for Dry Age-related Macular Degeneration
4 Dry Age-related Macular Degeneration Market Analysis Overview at a Glance
5 Executive Summary of Dry Age-related Macular Degeneration
6 Dry Age-related Macular Degeneration Epidemiology and Market Methodology
7 Dry Age-related Macular Degeneration Epidemiology and Patient Population
8 Dry Age-related Macular Degeneration Patient Journey
9 Dry Age-related Macular Degeneration Treatment Algorithm, Dry Age-related Macular Degeneration Current Treatment, and Medical Practices
10 Key Endpoints in Dry Age-related Macular Degeneration Clinical Trials
11 Dry Age-related Macular Degeneration Marketed Therapies
12 Dry Age-related Macular Degeneration Emerging Therapies
13 Dry Age-related Macular Degeneration: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Dry Age-related Macular Degeneration
16 Dry Age-related Macular Degeneration Market Key Opinion Leaders Reviews
18 Dry Age-related Macular Degeneration Market Drivers
19 Dry Age-related Macular Degeneration Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Dry Age-related Macular Degeneration Epidemiology 2032
DelveInsight’s “Dry Age-related Macular Degeneration – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dry Age-related Macular Degeneration epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dry Age-related Macular Degeneration Pipeline 2023
“Dry Age-related Macular Degeneration Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dry Age-related Macular Degeneration market. A detailed picture of the Dry Age-related Macular Degeneration pipeline landscape is provided, which includes the disease overview and Dry Age-related Macular Degeneration treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
